文献速递免疫规划卫生政策与健康促进

异基因造血干细胞移植后成人初次疫苗接种的单中心回顾性疗效分析

Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis.
PubMed 文献 · Vaccine · 2021-05-25

该研究回顾性分析了84例2008至2015年间接受异基因造血干细胞移植的成人患者,按EBMT推荐进行初次疫苗接种后的免疫应答预测因素。结果显示89.3%的患者对DTaP-Hib-IPV联合疫苗中至少3个组分产生保护性抗体,Hib和破伤风应答率最高,百日咳杆菌应答率最低;低B细胞计数和低IgG水平是接种应答失败的显著危险因素。

要点

  • 89.3%的alloHSCT患者对DTaP-Hib-IPV中至少3个组分产生保护性抗体。
  • 低B细胞计数(p<0.001,界值0.05 B细胞/nl)和低IgG水平(p=0.026)是应答失败的显著危险因素。
  • Hib(97.4%)、破伤风(95.2%)和肺炎球菌疫苗(83.6%)应答率较高,百日咳杆菌仅68.3%。

核心结论

  • 当前推荐的疫苗接种策略可使大多数alloHSCT患者获得血清保护。
  • 低B细胞计数和低IgG水平是疫苗接种应答失败的显著危险因素。

研究设计与样本

  • 单中心回顾性分析,纳入2008至2015年间接受alloHSCT的84例成人患者(移植时年龄18.6-70.6岁)。
  • 所有患者无复发生存≥9个月、至少连续接种3次疫苗且接种前后3个月内未使用静脉免疫球蛋白。
  • 对67例患者亚组分析了肺炎球菌结合疫苗的免疫应答。

主要发现

  • 89.3%(n=75)的患者对DTaP-Hib-IPV中至少3个组分达到保护性滴度,被认定为应答者;10.7%(n=9)为无应答者。
  • 各组分应答率:Hib 97.4%、破伤风95.2%、肺炎球菌疫苗83.6%、百日咳杆菌68.3%。
  • 低B细胞计数(p<0.001;界值0.05 B细胞/nl)和低IgG水平(p=0.026;应答者平均IgG 816 mg/dl vs 无应答者475 mg/dl)是应答失败的显著危险因素。
  • 既往cGvHD有影响疫苗接种应答的趋势:无应答者中88.9%有既往cGvHD,应答者中仅54.7%(p=0.073)。

关键数值与推荐

  • DTaP-Hib-IPV疫苗接种后,对至少3个组分达到保护性抗体滴度定义为应答者。
  • 低B细胞计数界值为0.05 B细胞/nl(p<0.001)。
  • 应答者平均IgG为816 mg/dl,无应答者为475 mg/dl(p=0.026)。

临床怎么用

  • alloHSCT后成人患者可按EBMT推荐进行初次疫苗接种,多数可获得血清保护。
  • 接种前评估B细胞计数和IgG水平有助于识别应答失败高风险患者。
  • 对低B细胞计数或低IgG水平患者,可考虑加强免疫应答监测。

局限性

  • 单中心回顾性分析,样本量有限(84例,亚组67例)。
  • 仅分析血清学应答,未评估临床感染结局。
  • 既往cGvHD与应答失败的关联仅为趋势(p=0.073),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (alloHSCT) results in a loss of humoral immunity and subsequent risk for severe infections. Thus, re-vaccination is required but may fail due to incomplete immune reconstitution. We retrospectively analyzed predictors of immune response to primary vaccination applied according to the EBMT (European Blood and Marrow Transplantation Group) recommendations. Serologic response to vaccination against diphtheria (D), tetanus (T), Bordetella pertussis (aP) and Haemophilus influenzae (Hib) (administrated as combined DTaP-Hib-IPV vaccination) was studied in 84 alloHSCT patients transplanted between 2008 and 2015 (age at alloHSCT: 18.6-70.6 years). All patients with a relapse-free survival of ≥9 months, at least 3 consecutive vaccinations and absence of intravenous immunoglobulin administration within 3 months before and after vaccination met the primary inclusion criteria. Additionally, immunological response to a pneumococcal conjugate vaccine was analyzed in a subgroup of 67 patients. Patients' characteristics at the time of first vaccination were recorded. Responses were measured as vaccine-specific antibody titers. Regarding DTaP-Hib-IPV vaccination, 89.3% (n = 75) of all patients achieved protective titers to at least 3 of the 4 vaccine components and were thus considered responders. 10.7% (n = 9) of the patients were classified as non-responders with positive immune response to less than 3 components. Highest response was observed for Hib (97.4%), tetanus (95.2%) and pneumococcal vaccination (83.6%) while only 68.3% responded to vaccination against Bordetella pertussis. Significant risk factors for failure of vaccination response included low B cell counts (p < 0.001; cut-off: 0.05 B cells/nl) and low IgG levels (p = 0.026; mean IgG of responders 816 mg/dl vs. 475 mg/dl of non-responders). Further, a trend was observed that prior cGvHD impairs vaccination response as 88.9% of the non-responders but only 54.7% of the responders had prior cGvHD (p = 0.073). The results demonstrate, that the currently proposed vaccination strategy leads to seroprotection in the majority of alloHSCT patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sattler C, Hoffmann P, Herzberg PY, et al. Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis. Vaccine. 2021. PMID: 34049733. doi:10.1016/j.vaccine.2021.04.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。